Reviva Pharmaceuticals Holdings, Inc. (RVPH) has a negative trailing P/E of 0.0, meaning the company is currently unprofitable on a trailing twelve-month (TTM) basis. The forward P/E of 6.6 based on analyst estimates suggests a return to profitability is expected. Trailing earnings yield is -688,215,374.27%, forward earnings yield 15.24%.
Criteria proven by this page:
Overall SharesGrow Score: 35/100 with 1/7 criteria passed.
| Year | P/E (TTM) | PEG Ratio | P/B Ratio | P/S Ratio | Dividend Yield |
|---|---|---|---|---|---|
| 2019 | -12.2 | 0.00 | 0.00 | 0.00 | - |
| 2020 | -34.5 | 0.16 | -4.30 | 0.00 | - |
| 2020 | -7.1 | -0.02 | 4.90 | 0.00 | - |
| 2021 | -5.0 | 0.09 | 1.49 | 0.00 | - |
| 2022 | -3.4 | -0.02 | 9.88 | 0.00 | - |
| 2023 | -3.1 | -0.23 | 21.43 | 0.00 | - |
| 2024 | -2.0 | 0.04 | 73.84 | 0.00 | - |
| 2025 | 0.0 | 0.00 | 0.00 | 0.00 | - |
| Year | EPS (Diluted) | Revenue | Net Income | Net Margin |
|---|---|---|---|---|
| 2018 | $0.28 | $0.00 | $-1.68M | - |
| 2019 | $-0.31 | $0.00 | $-846.83K | - |
| 2020 | $-1.24 | $0.00 | $-3.78M | - |
| 2021 | $-0.58 | $0.00 | $-8.52M | - |
| 2022 | $-1.45 | $0.00 | $-24.34M | - |
| 2023 | $-1.65 | $0.00 | $-39.26M | - |
| 2024 | $-0.90 | $0.00 | $-29.92M | - |
| 2025 | $-5.48 | $0.00 | $-19.86T | - |
| Year | EPS (Avg) | EPS Range | Revenue (Avg) | Revenue Range | Analysts |
|---|---|---|---|---|---|
| 2026 | $-3.27 | $-5.52 – $-2.00 | $5M | $5M – $5M | 4 |
| 2027 | $-2.25 | $-3.08 – $-1.40 | $137.3M | $137.3M – $137.3M | 3 |
| 2028 | $-3.49 | $-6.71 – $-0.27 | $185.75M | $185.75M – $185.75M | 2 |
| 2029 | $-5.21 | $-5.21 – $-5.21 | $378.96M | $378.96M – $378.96M | 1 |
| 2030 | $0.48 | $0.48 – $0.48 | $134.12M | $134.12M – $134.12M | 1 |
